A prominent oncologist with an international reputation for cancer research will lead the new Wesley Center for Immunotherapy at University Hospitals (UH) Seidman Cancer Center as well as the Division of Hematology. Koen van Besien, MD, PhD, comes to UH Seidman Cancer Center from New York-Presbyterian Hospital, where he has been Director of the Stem Cell Transplant Program and an attending physician. He is also Professor of Medicine at Weill Cornell Medical College in New York City.
Dr. van Besien will lead the Wesley Center for Immunotherapy at UH Seidman Cancer Center, a cellular therapy facility that generates CAR T-cell, NK-cell, and other cellular-based therapies. Physician-scientists engage in groundbreaking research and bring new, life-extending immunotherapies to patients. UH experts are creating cells for treatment in just 8 days, an innovation that allows physicians to deliver life-enhancing therapy more quickly than previously possible.
Koen van Besien, MD, PhD
Expanding the Field
Dr. van Besien has made numerous contributions to the field of cellular therapy and stem cell transplantation. Most recently, he has focused on methods to extend the use of transplantation to more patients in need. His group has recently reported the first successful transplant for a patient with human immunodeficiency virus (HIV) and leukemia using a haplo-cord graft—a unique procedure developed by his team. The patient remains free of HIV and leukemia more than 4 years after transplantation.
Dr. van Besien is Editor in Chief of the Journal of Leukemia and Lymphoma and a member of the editorial review boards of the journals Bone Marrow Transplantation and Biology of Blood and Marrow Transplantation. His National Institutes of Health–supported research has been published in more than 300 peer-reviewed papers.
Dr. van Besien completed medical school and clinical training at College ND de la Paix in Namur and the University of Leuven, both in Belgium. He holds a PhD from the University of Maastricht in the Netherlands. He completed his hematology/oncology fellowship at Indiana University and in Bruges, Belgium. Dr. van Besien has served on the faculty of MD Anderson Cancer Center in Houston. He also directed transplant programs at the University of Illinois for 4 years and at the University of Chicago for a decade. He is fluent in five languages: English, Dutch, German, Spanish, and French.
